ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLV..ROMK..AL..............................JDIM350 (Ver 2.1 Jan 2001) 1620000/01081148EUROPEAN PATENT APPLICATIONA320030305EP00203932.919930825EnEnEn93551519920825US20030305200310200103072001107 7C 07D 473/00 A 7C 07D 405/04 B 7A 61K 31/52 B 7C 07F 9/6561 BdeEnantiomerisch reine Beta-D-Dioxolan-NukleosideenEnantiomerically pure beta-D-dioxolane-nucleosidesfrNucléosides de béta-D-Dioxolane énantiomériquement Purs1A/B93920366.7065677819940303UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.00877875P025987EPGEORGIA RESEARCH FOUNDATION, INC., UNIVERSITY OFThe University of GeorgiaAthens, GA 30602USEMORY UNIVERSITY00382081P025987EP1380 South Oxford Road, N.E.Atlanta, GA 30322USChu, Chung K.120 Orchard Knob LaneAthens, GA 30605USSchinazi, Raymond F.1524 Regency Walk DriveDecatur, GA 30033USHallybone, Huw Georgeet al00053031Carpmaels and Ransford, 43 Bloomsbury SquareLondon WC1A 2RAGBATBECHDEDKESFRGBGRIEITLILUMCNLPTSEALLTLVMKROSI20030305200310

A method and composition for the treatment of humans infected with HIV that includes administration of an HIV treatment amount of an enantiomerically pure β-D-dioxolanyl purine nucleoside of formula (I), wherein R is OH, Cl, NH₂, or H, or a pharmaceutically acceptable salt or derivative of the compound, optionally in a pharmaceutically acceptable carrier or diluent.